681 related articles for article (PubMed ID: 10101019)
21. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
22. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
[TBL] [Abstract][Full Text] [Related]
23. Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice.
Vane J
Jpn J Cancer Res; 1997 Nov; 88(11):inside front cover. PubMed ID: 9439674
[No Abstract] [Full Text] [Related]
24. [A heterogenous drug class. NSAID: classification and spectrum of action].
Ulbrich H; Dannhardt G
Pharm Unserer Zeit; 2002; 31(2):146-54. PubMed ID: 11977450
[No Abstract] [Full Text] [Related]
25. Closing in on a stomach-sparing aspirin substitute.
Service RF
Science; 1996 Sep; 273(5282):1660. PubMed ID: 8830410
[No Abstract] [Full Text] [Related]
26. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase (COX) inhibitors: a comparative QSAR study.
Garg R; Kurup A; Mekapati SB; Hansch C
Chem Rev; 2003 Mar; 103(3):703-32. PubMed ID: 12630850
[No Abstract] [Full Text] [Related]
29. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
30. [COX-2 specific inhibitors are similar--and different].
Aly A
Lakartidningen; 2000 Sep; 97(38):4181-2. PubMed ID: 11068393
[No Abstract] [Full Text] [Related]
31. [Selective COX-2 non-steroidal anti-inflammatory agents and gastrointestinal toxicity].
Zaragoza A; Llorente MJ; García MM; Ramírez JJ; Lloret G; Machancoses A
Rev Esp Enferm Dig; 2001 Dec; 93(12):819-20. PubMed ID: 11995364
[No Abstract] [Full Text] [Related]
32. Possible inconsistencies in study on cyclooxygenase.
Kay-Mugford T; Conlon P
Am J Vet Res; 1999 Mar; 60(3):275-6. PubMed ID: 10188806
[No Abstract] [Full Text] [Related]
33. [Biological functions of cyclooxygenase 2: control of its expression and activity].
Jacquemin C
J Soc Biol; 2000; 194(3-4):189-93. PubMed ID: 11324321
[TBL] [Abstract][Full Text] [Related]
34. [The use of non-steroidal anti inflammatory drugs (NSAIDs)--COX-2 inhibitors].
Tishler M; Langevetiz P; Nesher G
Harefuah; 2002 Oct; 141(10):920-1. PubMed ID: 12420601
[No Abstract] [Full Text] [Related]
35. [Cyclooxygenases, structure, biological functions and the role in inflammation processes].
Kotyla PJ; Sliwińska-Kotyla B; Kucharz EJ
Pol Arch Med Wewn; 2001 Oct; 106(4):963-6. PubMed ID: 11993417
[No Abstract] [Full Text] [Related]
36. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
37. Rational use of analgesic and antiinflammatory drugs.
Crofford LJ
N Engl J Med; 2001 Dec; 345(25):1844-6. PubMed ID: 11752364
[No Abstract] [Full Text] [Related]
38. [Specificity, action, indications and safety. Criteria for the use of COX-2 inhibitors].
Wigand R
Pharm Unserer Zeit; 2002; 31(2):190-8. PubMed ID: 11977455
[No Abstract] [Full Text] [Related]
39. [A new NSAID selective COX-2 inhibitor].
Ledro Cano D; Gómez Rodríguez B; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban J; Herrerías Gutiérrez J
Rev Esp Enferm Dig; 1999 Aug; 91(8):598. PubMed ID: 10491496
[No Abstract] [Full Text] [Related]
40. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
